The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Biologics License Application for Rixathon (rituximab biosimilar) accepted for review by FDA
On 12th September 2017, the Biologics License Application (BLA) submitted by Sandoz (Novartis) for Rixathon (GP2013; rituximab biosimilar) to the U.S. Food and Drug Administration (FDA) was accepted.
The BLA was supported by data from the phase III confirmatory ASSIST-FL study (NCT01419665), which aimed to compare the efficacy and safety, as well as the Pharmacokinetics (PK) and Pharmacodynamics (PD), of cyclophosphamide, vincristine, and prednisone combined with either Rixathon (GP2013-CVP) or rituximab (R-CVP) in patients with newly diagnosed, advanced stage FL (n=629).
Key Highlights:
- Treatment phase = 6 months; maintenance phase = 2 years; follow-up = 3 years
- Pts randomly assigned to 8 cycles of CP2013-CVP (n=314) or R-CVP (n=315)
- Pts who achieved CR or PR entered the double-blind maintenance phase, and received either CP2013 or rituximab
- ORR with GP2013-CVP was 87.1% (CR = 14.8%; PR = 72.3%) versus 5% (CR = 13.4%; PR = 74.1%) with R-CVP
- Median PFS and OS have not been reached
- PK and PD of Rixathon was similar to rituximab
- Incidence of SAEs was similar in GP2013-CVP and R-CVP arms (22.8% vs 0%, respectively)
- Most frequent SAE in GP2013-CVP and R-CVP arms was febrile neutropenia (4.8% vs 9%, respectively)
- As of 10th July 2015, 35 deaths have been recorded (GP2013-CVP n=18; R-CVP n=17)
- Most common cause of death in CP2013-CVP and R-CVP arms was Non-Hodgkin Lymphoma (2.6% vs 9%, respectively)
- Antidrug antibodies developed in 1.9% (n=5) of GP2013-CVP pts and 1.1% (n=3) R-CVP pts
If approved, the indications for Rixathon will include Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBLC), and Chronic Lymphocytic Leukemia (CLL). The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion for Rixathon in April 2017 (read more here), and this was followed by European approval in June.
References